Mar 14, 2013|
Will compulsory licensing become the norm?
It has now been a year since the Indian Patent office granted its first 'compulsory license' for a cancer drug - Nexavar (Sorafenib Tosylate) to Natco Pharma. Naturally the innovator of the drug was discontented by this decision. Let us now take a look at how things have progressed on this front.
As per the WTO (World Trade Organization) - "Compulsory licensing is when a government allows someone else to produce the patented product or process without the consent of the patent owner. It is one of the flexibilities on patent protection included in the WTO's agreement on intellectual property - the TRIPS (Trade-Related Aspects of Intellectual Property Rights) Agreement".
The TRIPS Agreement does list a number of conditions for issuing compulsory licenses, in Article 31. In particular:
Further, as per the TRIPS agreement, compulsory licensing is applicable only when the generic copy is produced mainly for the domestic market, not for export. In 2003, Malaysia was among the initial few countries which had promoted drugs through compulsory licensing. However now, many Asian countries such as Indonesia, Thailand, followed by India in 2012 are taking compulsory licensing route to promote cheaper medicines in their respective markets.
- normally the person or company applying for a license has to have tried to negotiate a voluntary license with the patent holder on reasonable commercial terms. Only if that fails can a compulsory license be issued. Thus, in 2010, Natco had filed for voluntary license for Nexavar, however Bayer had refused to grant license filed by Natco) and
- even when a compulsory license has been issued, the patent owner has to receive payment. In this matter, the TRIPS Agreement says, "the right holder shall be paid adequate remuneration in the circumstances of each case, taking into account the economic value of the authorization", but it does not define "adequate remuneration" or "economic value". (As per public sources, Natco will have to pay royalty of 6% to Bayer for sale of Nexavar in India)
The impact of pricing differentiation
Price difference plays an important role in getting compulsory license. In Natco's case too, the company was able to get the rights of compulsory licensing, as it was able to produce the drug at a significantly lower cost. Indeed, Natco's drug is sold at a 97% discount to the price of the innovator's drug.
But there were other important reasons too - Public requirement or unmet need and manufacturing outside India. As per various public sources, almost 90% of the MNC drugs are imported in India.
Most of the time the drugs which are life threatening in therapies such as cancer, HIV etc are given rights of compulsory licensing.
After Nexavar's approval, Natco is now considering additional launches in the oncology segment and other therapeutic segments. The company is working on approximately 4-5 such drugs, which have the potential to get compulsory license.
Government is now looking to add new cancer drugs in the list
The government has started the process of granting three more compulsory licenses, on cancer treatments from Roche and Bristol-Myers Squibb.
The licensing moves apply to Roche's breast cancer drug Herceptin (Trastuzumab), and Bristol-Myers Squibb's leukemia treatment Sprycel (dasatinib) and breast cancer therapy Ixempra (Ixabepilone). It would be the first round of new compulsory licenses since India issued its first in March, on Bayer's kidney cancer treatment Nexavar.
Stance of the Innovator companies
In Nexavar's case, Bayer had filed various litigation suits against the Indian patent office as well as Natco. Various reasons were given by Bayer to protect its brand. But nothing has been working so far.
Recently, the Indian Intellectual Property Appellate Board (IPAB) upheld a decision to allow Natco Pharma to sell a generic version of Bayer's cancer drug Nexavar. However, the royalty payment to Bayer was increased from 6% to 7%.
Competition is already intensifying in the domestic pharma market and there would be further challenges in store in the event that the new drug Pricing Policy comes into force. Thus, there could be some headwinds for the domestic pharma market going forward. In such a scenario, compulsory licensing will act as a low competition opportunity for a period of time. Besides Nexavar, Natco has already begun work on more such opportunities, and in that sense is ahead of the curve than other Indian companies. However as the government is in the process of bringing more drugs under compulsory licensing, the possibility of competition entering this space too cannot be ruled out.
But there is the other side of the coin too. Though compulsory licensing looks attractive, there are barriers which could be raised by the innovator of the drugs, which should also be considered by investors. Thus, even after a company gets compulsory license, the innovator could take various steps to protect its patent and reduce the value for the generic company. Thus investors should be aware about such actions. Ultimately, the opportunity from compulsory license would depend upon the nature and size of the drug and the patents surrounding the same and should be evaluated accordingly.
||Bhavita Nagrani (Research Analyst) is a Chartered Financial Analyst (ICFAI) with nearly six years of experience in the field of equity research. She has a deep understanding of the global as well as the domestic Healthcare industry and keenly tracks the developments therein. When it comes to stock investing, she is a strong advocate of the bottom-up approach to stock picking and has a remarkable ability to discern nuances in the business models of companies belonging to the same industry. Bhavita is the contributor to our large cap franchise, StockSelect.
More Views on News
Aug 14, 2017
A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.
Aug 14, 2017
GST impact coupled with price erosion in US leads to lower profits for the quarter.
Aug 8, 2017
Profits plunge due to higher raw material costs.
Jun 16, 2017
Here's what you can expect from The 5 Minute Wrapup in the coming months and years.
Jun 23, 2017
Net Profit lower due to exceptional items in the previous year.
More Views on News
Aug 17, 2017
A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.
Aug 10, 2017
Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.
Aug 12, 2017
The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.
Aug 10, 2017
Bitcoin hits an all-time high, is there more upside left?
Aug 16, 2017
Ensure your financial Independence, and pledge to start the journey towards financial freedom today!
Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement. LEGAL DISCLAIMER:
Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here
. The performance data quoted represents past performance and does not guarantee future results.SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407